J&J Advances Pipeline With Yondelis, Carisbamate Filings
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson progressed its pipeline with the filing of two novel drugs late in 2008: trabectedin (marketed outside the U.S. as Yondelis) for the treatment of relapsed ovarian cancer, and carisbamate for the adjunctive treatment of partial onset seizures